Literature DB >> 3097901

Histopathology of BCG and thiotepa treated bladders.

P Guinan, M Shaw, V Ray.   

Abstract

In an effort to characterize the pathophysiological differences between the modes of action of BCG and thiotepa in the treatment of superficial bladder cancer, normal female rats received weekly intravesical instillations of both agents. The animals were sacrificed and their bladders were examined pathologically to determine if there were histological differences between the cellular infiltrates found in the BCG and thiotepa treated bladders. Mononuclear cells, particularly T-cells, predominated in the BCG treated bladders whereas polymorphonucleated cells predominated in the thiotepa treated bladders suggesting that there may be an immune aspect to the former therapy. The presence of T-cells following BCG therapy suggest a T-cell mediated immune response.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3097901     DOI: 10.1007/bf00441116

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  27 in total

1.  Letter: Effect of BCG on haemopoietic stem cells.

Authors:  P Pouillart; T Palangie; L Schwarzenberg; H Brugerie; J Lhéritier; G Mathé
Journal:  Biomedicine       Date:  1975-12-20

2.  Effect of Myobacterium bovis (strain Bacillus Calmette-Guérin) on macrophage production by the bone marrow of tumor-bearing mice.

Authors:  B Fisher; S Taylor; M Levine; E Saffer; E R Fisher
Journal:  Cancer Res       Date:  1974-07       Impact factor: 12.701

Review 3.  BCG and cancer (first of two parts).

Authors:  R C Bast; B Zbar; T Borsos; H J Rapp
Journal:  N Engl J Med       Date:  1974-06-20       Impact factor: 91.245

4.  Introduction of "natural" killer' cells by BCG.

Authors:  S A Wolfe; D E Tracey; C S Henney
Journal:  Nature       Date:  1976-08-12       Impact factor: 49.962

Review 5.  Immunotherapy of superficial bladder cancer.

Authors:  A Shapiro; D Kadmon; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1982-11       Impact factor: 7.450

6.  Intravesical thio-tepa: a study of 3H-thymidine uptake in normal urothelium and FANFT-induced tumors in rats.

Authors:  P T Nieh; J J Daly; R J Irwin; G R Prout
Journal:  Invest Urol       Date:  1979-05

7.  Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly I:C/poly-L-lysine and cis platinum in murine bladder cancer.

Authors:  A Shapiro; T L Ratliff; D M Oakley; W J Catalona
Journal:  J Urol       Date:  1984-01       Impact factor: 7.450

8.  The effect of intramural injection of immunotherapeutic agents on bladder histology and systemic humoral response.

Authors:  N E Albert; F C Sparks; B Lytton
Journal:  Invest Urol       Date:  1978-09

9.  BCG treatment of malignant pleural effusions in the rat.

Authors:  M V Pimm; D G Hopper; R W Baldwin
Journal:  Br J Cancer       Date:  1976-10       Impact factor: 7.640

10.  BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells.

Authors:  R W Baldwin; M V Pimm
Journal:  Br J Cancer       Date:  1973-01       Impact factor: 7.640

View more
  6 in total

1.  Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guerin.

Authors:  M Peuchmaur; G Benoit; A Vieillefond; A Chevalier; G Lemaigre; E D Martin; A Jardin
Journal:  Urol Res       Date:  1989

2.  Metabolic studies on rabbit bladder smooth muscle and mucosa.

Authors:  J A Hypolite; P A Longhurst; C Gong; J Briscoe; A J Wein; R M Levin
Journal:  Mol Cell Biochem       Date:  1993-08-11       Impact factor: 3.396

3.  Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.

Authors:  E C de Boer; W H de Jong; A P van der Meijden; P A Steerenberg; F Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1991

4.  Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guérin.

Authors:  J S Shin; J H Park; J D Kim; J M Lee; S J Kim
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

5.  Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.

Authors:  W H De Jong; E C De Boer; A P Van der Meijden; P Vegt; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig.

Authors:  A P van der Meijden; W H de Jong; E C de Boer; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1989
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.